Q1 2026 · 13F-HR
Deep Track Capital, LPholdings as filed
Filed 2026-05-15 · accession 0001856083-26-000003
$6.12B
Reported value
63
Positions
2026-03-31
Period end
The Brief · Deep Track Capital, LP · Q1 2026
AI · grounded in 13F
Deep Track Capital, LP closed its entire position in Dynavax Technologies Corp DVAX, reducing exposure by $241.87M. The fund established three new positions, led by Alumis Inc ALMS at $149.2M and Nuvalent Inc NUVL at $141M. Additionally, the fund trimmed its holdings in BioMarin Pharmaceutical Inc BMRN by 50% and CytoKinetics Inc CYTK by 58.8%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78464A870 | XBI | SPDR SERIES TRUST | $1.28B | 20.9% | 10,000,000 | PUT | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $308.4M | 5.04% | 3,338,241 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $286.3M | 4.68% | 11,526,971 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $252.5M | 4.12% | 3,600,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $249.9M | 4.08% | 4,300,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $206.3M | 3.37% | 4,279,848 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC. | $185.9M | 3.04% | 1,100,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $182.3M | 2.98% | 4,532,374 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $166.7M | 2.72% | 19,686,282 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $165.2M | 2.70% | 4,106,067 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $149.2M | 2.44% | 6,772,595 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $146.4M | 2.39% | 1,950,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $141.0M | 2.30% | 1,376,324 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $127.0M | 2.07% | 3,590,323 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $125.4M | 2.05% | 3,158,041 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $119.5M | 1.95% | 6,408,863 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $103.8M | 1.70% | 3,477,562 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $99.8M | 1.63% | 2,034,203 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $98.4M | 1.61% | 6,345,244 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S | $98.3M | 1.61% | 3,663,250 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $90.6M | 1.48% | 1,374,320 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $89.0M | 1.45% | 1,722,797 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $82.7M | 1.35% | 3,352,804 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $82.3M | 1.34% | 2,757,569 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $80.8M | 1.32% | 4,062,500 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $67.3M | 1.10% | 12,161,496 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $65.0M | 1.06% | 1,150,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $62.5M | 1.02% | 841,445 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $58.2M | 0.95% | 1,931,884 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $57.5M | 0.94% | 2,750,000 | Common | SOLE |
| 24477V105 | DFTX | DEFINIUM THERAPEUTICS INC | $56.7M | 0.93% | 3,000,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $56.6M | 0.92% | 1,073,877 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $47.3M | 0.77% | 31,720,278 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $46.1M | 0.75% | 600,000 | Common | SOLE |
| 21900C308 | CRMD | CORMEDIX INC | $42.6M | 0.70% | 6,274,076 | Common | SOLE |
| 04650F101 | ATAI | ATAIBECKLEY INC | $42.5M | 0.69% | 12,000,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $40.7M | 0.67% | 1,283,979 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $38.5M | 0.63% | 1,000,000 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $36.5M | 0.60% | 2,491,539 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $36.3M | 0.59% | 2,000,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $36.1M | 0.59% | 1,078,710 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $35.0M | 0.57% | 9,345,000 | Common | SOLE |
| 922967104 | MANE | VERADERMICS INC | $31.6M | 0.52% | 500,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $30.4M | 0.50% | 5,740,850 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $29.8M | 0.49% | 4,377,572 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $27.3M | 0.45% | 1,393,944 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $26.2M | 0.43% | 6,339,535 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $25.7M | 0.42% | 3,565,062 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $24.7M | 0.40% | 1,956,867 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $24.0M | 0.39% | 285,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $21.5M | 0.35% | 2,643,542 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $21.4M | 0.35% | 9,487,745 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $19.6M | 0.32% | 820,765 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $19.4M | 0.32% | 7,419,355 | Common | SOLE |
| 71535D106 | PSNL | PERSONALIS INC | $19.1M | 0.31% | 3,000,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $16.5M | 0.27% | 1,187,290 | Common | SOLE |
| 74346M505 | PMN | PROMIS NEUROSCIENCES INC | $10.6M | 0.17% | 835,655 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $8.3M | 0.14% | 453,686 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $6.8M | 0.11% | 1,222,453 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $6.8M | 0.11% | 1,500,000 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $6.3M | 0.10% | 1,313,137 | Common | SOLE |
| 090168105 | BLLN | BILLIONTOONE INC | $3.9M | 0.06% | 50,000 | Common | SOLE |
| 01626L204 | ALGS | ALIGOS THERAPEUTICS INC | $3.3M | 0.05% | 444,110 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.